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1. Introduction
Hematopoietic stem cell transplantation (HSCT) has a half-century history. It is currently an
indispensable treatment for not only incurable blood diseases such as aplastic anemia and
severe hemolytic anemia, but also malignant hematological diseases such as leukemia and
lymphoma. Although allergenic HSCT is also used to treat hereditary diseases, its indica‐
tions are restricted because of critical complications including regimen-related toxicities in‐
volving conditioning, infection, and graft-versus-host disease.
Studies in recent decades have shown that HSCT can have a long-term effect in the treat‐
ment of hereditary diseases involving a responsible gene in hematogenous cells. Although
the first successful gene therapy using lymphocytes or bone marrow cells for a patient with
adenosine deaminase (ADA) deficiency inspired great hope in the future of gene therapy
[1-3], subsequent gene therapy using HSCs for patients with X-linked severe combined im‐
munodeficiency (SCID-X1) resulted in tumorigenesis [4]. In addition to the self-renewal and
multilineage differentiation capacities of tissue stem cells, HSCs exhibit cell-cycle dormancy,
which complicates their use in gene therapy.
However, as technological advances have increased the safety and efficiency of introduc‐
ing genes into HSCs, gene therapy with HSCs is attracting attention again. In this chapter,
advances in the technology of HSC gene therapy, e.g., vector design to avoid genotoxicity
and  increase  transgenic  efficiency  by  taking  advantage  of  the  special  characteristics  of
HSCs, are reviewed. In addition, recent studies on HSC gene therapy for various heredita‐
ry diseases, such as thalassemia, Fanconi anemia, hemophilia, primary immunodeficiency,
mucopolysaccharidosis,  Gaucher  disease,  and  X-linked  adrenoleukodystrophy  (X-ALD)
are discussed.
© 2013 Tsuruta; licensee InTech. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
2. Characteristics of HSCs and gene therapy
The concept of the HSC was introduced by Till and McCulloch in 1961 [5]. Although a healthy
adult produces approximately 1 trillion blood cells each day, they are considered to originate
from a single HSC which can potentially be transplanted into a mouse [6, 7]. Generally stem
cells are defined as cells capable of self-renewal and multilineage differentiation. In addition to
these two characteristics, HSCs have the capability of cell-cycle dormancy, i.e. to enter a state of
dormancy (G0 phase) in the cell cycle and can continue blood cell production over a lifetime
while protecting themselves from various kinds of stress [8].
Fig. 1 shows HSC surface markers and the typical cytokines regulating HSCs. Stem cell factor
(SCF) and thrombopoietin (TPO) are important direct cytokine regulators of HSCs. Although
SCF promotes the proliferation and differentiation of hematopoietic progenitor cells, it is
thought to not be essential for the initiation of hematopoiesis and HSC self-renewal [9]. TPO
and its receptor, c-Mpl, are thought to play important roles in early hematopoiesis from HSCs.
In contrast to the CD34+CD38-c-Mpl- population, CD34+CD38-c-Mpl+ cells show significantly
better HSC engraftment [10]. Mice lacking either TPO or c-Mpl have deficiencies in progenitor
cells of multiple hematopoietic lineages [11]. TPO-mediated signal transduction for the self-re‐
newal of HSCs is negatively regulated by the intracellular scaffold protein Lnk [12, 13]. A sig‐
nal from angiopoietin-1 via Tie2 regulates HSC dormancy by promoting the adhesion of HSCs
to osteoblasts in the bone marrow niche and maintains long-term repopulating activity [14].
Although cytokine-induced lipid raft clustering of the HSC membrane is essential for HSC re-
entry into the cell cycle, transforming growth factor-β (TGF-β) inhibits lipid raft clustering and
induces p57Kip2 expression, leading to HSC dormancy [15, 16]. Recently, the hypoxic niche of
HSCs has been demonstrated. It, along with the osteoblastic and vascular niches, are important
for HSC dormancy [17-19]. They are targets in HSC gene therapy [20].
Figure 1. Hematopoietic stem cell (HSC) surface markers and typical cytokines that regulate HSCs. Stem cell fac‐
tor (SCF) promotes the proliferation and differentiation of HSCs. Thrombopoietin (TPO) and its receptor, c-Mpl, play
important roles in early hematopoiesis, especially self-renewal. Signals from angiotensin-1 via Tie2 and transforming
growth factor -β via its receptors regulate HSC dormancy. (This figure is based on the illustration by BioLegend, Inc.
San Diego, CA, U.S.A. http://www.biolegend.com/cell_markers)
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While making a HSC with few opportunities for cell division into a transgenic target, it is
important to design a safe and efficient vector for inserting a gene into the host chromo‐
some. Furthermore, since a hematogenous cell also has many cells which exhibit its function
in the specialization process to a mature effector cell, it is also important to select differentia‐
tion-specific or non-specific promoters or enhancers during the vector design process.
3. Vectors for HSC gene therapy
Vectors derived from the Retroviridae family, RNA viruses with reverse transcriptase activi‐
ty, are widely used for inserting genes in host chromosomes. Although adeno-associated vi‐
rus (AAV) vectors can also insert genes into host chromosomes, this process is inefficient
and partial. Gammaretroviruses and lentiviruses are members of the Retroviridae family
that are commonly used as vectors in HSC gene therapy. Generally, the former is called sim‐
ply a retroviral vector and the latter is called a lentiviral vector. When a gene is inserted in
the chromosome of an HSC with a Retroviridae vector, genotoxicity can occur.
3.1. Gammaretroviral (Retroviral) vectors
Retroviral vectors are commonly constructed from the Moloney murine leukemia virus
(MoMLV) genome. Retroviral genomes have a gag/pol gene that codes for viral structure
proteins, protease and reverse transcriptase, an env gene that codes for the envelope glyco‐
protein and the packaging signal. These genes are flanked by long terminal repeats (LTR)
which contain enhancers and promoters. A retroviral vector consists of a packaging plasmid
that does not have the packaging signal but does include the gag/pol gene, a transfer vector
with the packaging signal, and the target gene cDNA. After transfection of these plasmids
into producer cells (e.g., 297T cells, NIH3T3 cell, etc.), a target vector is obtained by collect‐
ing the culture solution.
Expression of a target gene can be inhibited by mechanisms such as methylation of CpG is‐
lands in the promoter region, insertion of a negative control region (NCR) into the LTR, and
the presence of a repressor binding site (RBS) downstream of the 5′ LTR. Other vectors, such
as the murine stem cell virus (MSCV) vector [21], the myeloproliferative sarcoma virus vec‐
tor, the negative control region deleted (MND) vector [22], and the MFG-S vector [23] were
developed to improve the efficiency of transgene expression; they are widely used in clinical
applications of gene therapy involving HSCs.
Since the retroviral viral genome cannot cross the nuclear membrane, it can be incorporated
into a chromosome only during the phase of mitosis when the nuclear membrane has disas‐
sembled. Since many HSCs are thought to exist in a dormant phase, insertions into the HSC
genome with a retroviral vector require a proliferation stimulus by cytokines. Although var‐
ious combinations of cytokines to suppress the decrease in HSC self-renewal have been
studied, stem cell factor (SCF), fms-related tyrosine kinase-3 (Flt-3) ligand, interleukin-3
(IL-3), TPO, among others, are commonly used [24, 25].
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3.2. Lentiviral vectors
Human immunodeficiency virus type 1 (HIV-1), the representative lentivirus, differs from
gammaretroviruses in that it can be incorporated during a non-mitotic phase. This is one ad‐
vantage of lentiviral vectors in HSC gene therapy.
Both lentiviruses and gammaretroviruses have gag, pol, and env genes sandwiched between
LTRs with promoter activity at both ends. In addition, lentiviruses have accessory genes (vif,
vpr, vpu, nef) and regulatory genes (tat, rev). Double-stranded cDNA produced from the viral
genome enters the cell, and a pre-integration complex is formed with a host protein. This
complex can pass through the pores of the nuclear membrane during non-mitotic phases, al‐
lowing the viral genome to be inserted into the host cell chromosome.
Figure 2. HIV provirus (A) and the four plasmids of a third-generation lentiviral vector (B). The viral long termi‐
nal repeats (LTRs), reading frames of the viral genes, splice donor site (SD), splicing acceptor site (SA), packaging signal
(Ψ), and rev-responsive element (RRE) are indicated. The packaging plasmid contains the gag and pol genes under the
influence of the CMV promoter, intervening sequences, and the polyadenylation site (polyA) of the human β-globin
gene. As the transcripts of the gag and pol genes contain cis-repressive sequences, they are expressed only if rev pro‐
motes their nuclear export by binding to the RRE. All tat and rev exons have been deleted, and the viral sequences
upstream of the gag gene have been replaced. The rev plasmid expresses rev cDNA. The SIN vector plasmid contains
HIV-1 cis-acting sequences and an expression cassette for the transgene. It is the only portion transferred to the target
cells and does not contain wild-type copies of the HIV LTR. The 5′ LTR is chimeric, with the RSV enhancer and promoter
replacing the U3 region to rescue transcriptional dependence on tat. The 3′ LTR has an almost completely deleted U3
region, which includes the TATA box. As the latter is the template used to generate both copies of the LTR in the inte‐
grated provirus, transduction of this vector results in transcriptional inactivation of both LTRs; thus, it is a self-inactivat‐
ing (SIN) vector. The envelope plasmid encodes a heterologous envelope to pseudotype the vector, here shown
coding for vesicular stomatitis virus (VSV)-G. Only the relevant parts of the constructs are shown (Reproduced with
modifications from [26]).
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Although first-generation lentiviral vectors included modification genes, they were re‐
moved in the second generation because it was discovered that the modification genes are
not required for infection during non-mitotic phases. In the third generation, further modifi‐
cations included the deletion of tat, use of multiple vector plasmids, and introduction of self-
inactivating (SIN) vectors. The structure of HIV-1 and a typical third-generation lentiviral
vector system are shown in Fig. 2 [26]. Approximately one-third of the HIV-1 genome has
been deleted, and the vector system has been divided into four plasmids, namely, the pack‐
aging plasmid, rev plasmid, SIN vector plasmid and envelope plasmid. To prevent produc‐
tion of wild type HIV-1, tat, a regulatory gene indispensable to viral reproduction was
deleted, and the rev gene was moved to a separate plasmid. Moreover, since the HIV-1 LTR
promoter is weak in the absence of tat, it was replaced with the cytomegalovirus (CMV) pro‐
moter in the packaging plasmid. Since an envelope plasmid can only infect CD4 positive
cells with a HIV-1 envelope, the envelope gene was replaced with the vesicular stomatitis
virus G glycoprotein (VSV-G) envelope. The SIN vector further improved safety by replac‐
ing the enhancer / promoter portion of the LTR, suppressing the activation of unnecessary
genes with the integrated gene (Fig. 3) [27].
Figure 3. Mechanism of gene activation induced by vector insertion. The genomic integration site of an MLV-
based retroviral vector is depicted. With this MLV vector design, the enhancer and promoter within the U3 region
(blue rectangle) of the long terminal repeat (LTR) drive transcription of the transgene (indicated by the parallel arrow
arising from the blue rectangle). Vector integration near Gene X is shown in the top panel. The enhancer elements
located in the U3 region (blue rectangle) of the vector can interact with the regulatory elements upstream of Gene X
to increase its basal transcription rate to inappropriately high levels, potentially altering the growth of the cell. Two
alternatives for eliminating the use of the powerful enhancer in the U3 region include (1) middle panel: use of a self-
inactivating (SIN) MLV-based vector in which the U3 region has been deleted. An internal cellular promoter is used to
drive transgene expression and (2) bottom panel: use of a SIN lentiviral vector in which U3 (yellow rectangle) has been
eliminated. This system also uses an internal cellular promoter to drive transgene expression (Reproduced with modifi‐
cation from [27]).
To improve the gene transfer into HSCs, Verhoeyen and colleagues designed lentiviral vec‐
tors displaying “early-acting cytokines” such as TPO and SCF. This vector can promote sur‐
vival of CD34 positive HSCs and achieve selective transduction of long-term repopulating
cells in a humanized mouse model (Fig. 4) [28, 29].
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Figure 4. Lentiviral vector particles (HIV-1) display recombinant membrane envelope proteins such as stem cell factor
(SCF), thrombopoietin (TPO), and vesicular stomatitis virus G glycoprotein (VSV-G). This vector can specifically target
vector particles to hematopoietic stem cells (HSCs) expressing c-kit and c-mpl receptors for SCF and TPO, respectively.
VSV-G envelope protein can bind to phospholipids in the HSC cell membrane. (Karlsson S, Gene therapy: efficient tar‐
geting of hematopoietic stem cells. Blood. 2005;106(10):3333)
3.3. Genotoxicity of viral vectors
The most serious problem with using viral vectors to incorporate a gene into a chromosome
is the potential development of clonal proliferative diseases such as leukemia, which was
observed in clinical trials involving gene therapy for SCID-X1 and chronic granulomatous
disease (CGD). Although this problem of genotoxicity represents a great hurdle in the devel‐
opment of clinical applications for gene therapy, there is promising ongoing research on the
mechanisms underlying genotoxicity and how to avoid it.
The mechanisms of retrovirus-induced oncogenesis are shown in Fig. 5 [30]. In oncogene
capture, an acute transforming replication-competent retrovirus captures a cellular proto-
oncogene and mediates transformation. This mechanism does not occur in replication-in‐
competent vectors. Second, the provirus 3′ LTR can trigger increased transcription of a
cellular proto-oncogene. Third, enhancers in the provirus LTRs can activate transcription
from nearby cellular proto-oncogene promoters. Fourth, a novel isoform can be expressed
Innovations in Stem Cell Transplantation112
when transcription from the provirus 5′ LTR creates a novel truncated isoform of a cellular
proto-oncogene via splicing. Fifth, an inserted provirus can disrupt transcription by causing
premature polyadenylation. The same mechanisms can occur in cellular oncogenesis when a
gene is inserted by a retroviral vector [30].
Figure 5. Retroviral mechanisms of oncogenesis. The detailed mechanisms are shown in the text. The integrated
provirus is indicated by two LTRs. Cellular proto-oncogene promoter and exons are indicated by black and grey boxes
respectively (Reproduced from [30]).
Even if a gene is inserted into a HSC similarly, it is also known that there are diseases which
may develop a tumor, and diseases a tumor is not accepted to be. Each type of virus has a
unique integration profile, and the following observations have been made [30]: (a) Different
retroviral vectors have distinct integration profiles. (b) The route of entry does not appear to
strongly affect distribution of integration sites. VSV-G–pseudotyped HIV vectors have an in‐
tegration profile similar to HIV virions with the native HIV envelope despite differences in
the route of entry. (c) The integration profile is largely independent of the target cell type,
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although the transcriptional program and epigenetic status of the target cell can influence
integration site selection. (d) For lentiviruses, which can integrate independently of mitosis,
the cell-cycle status of the target cell has only a modest effect on the distribution of integra‐
tion sites.
In order to avoid genotoxicity, various SIN vectors have been developed and improved.
In general, lentiviral vectors are considered to have a lower risk of oncogenesis than ret‐
roviral  vectors  [31].  However,  when a  HSC is  the  target  cell,  more  attention should be
required  because  tumorigenesis  can  occur  when  the  cell  with  the  inserted  gene  under‐
goes differentiation.
4. Clinical applications of HSC gene therapy
Diseases  in  which  gene  therapy  using  HSCs  are  being  studied  are  shown  in  Table  1.
They  are  roughly  divided  into  hematological  disorders,  immunodeficiencies,  and  meta‐
bolic  diseases.  Most  are congenital  or  hereditary diseases.  The characteristic  clinical  fea‐
tures  and recent  basic  science or  clinical  studies  on HSC gene therapy for  each disease
are discussed below.
Congenital hematopoietic disorders
β-thalassaemia
Fanconi anemia
Hemophilia
Primary immunodeficiencies
X-linked severe combined immunodeficiency (SCID-X1)
Adenosine deaminase deficiency (ADA-SCID)
Chronic granulomatous disease (CGD)
Wiskott-Aldrich syndrome (WAS)
Janus kinase 3 (JAK3) deficiency
Purine nucleoside phosphorylase (PNP) deficiency
Leukocyte adhesion deficiency type 1 (LAD-1)
Congenital metabolic diseases
Mucopolysaccharidosis (MPS) types I, II, III, VII
Gaucher disease
X-linked adrenoleukodystrophy (X-ALD)
Table 1. Clinical applications of hematopoietic stem cell gene therapy.
4.1. β-thalassemia
Hemoglobin  A (HbA),  comprising 98% of  adult  human hemoglobin,  is  a  tetramer  with
two α-globin and two β-globin chains combined with a heme group. β-thalassemia is an
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autosomal hemoglobin disorder caused by decreased β-globin chain synthesis.  Although
individuals with β-thalassemia minor (heterozygote) may be asymptomatic or have mild
to moderate  microcytic  anemia,  β-thalassemia major  (homozygote)  progresses  to  serious
anemia by one or two years of age, and hemosiderosis, iron overload caused by transfu‐
sion or increased iron absorption,  develops.  Since most patients develop life-threatening
complications such as heart failure by adolescence, HSCT has been performed in patients
with advanced disease  [32].  In  recent  years,  gene therapy using a  lentiviral  vector  con‐
taining a functional β-globin gene has been performed in an HbE/ β-thalassemia (βE/ β0)
transfusion-dependent  adult  male,  who  subsequently  did  not  require  transfusions  for
over 21 months [33].
The human β-globin locus is located in a large 70kb area which also contains some β-like
globulin genes (ε, Gγ, Aγ, δ, β). Gene switching takes place according to the development
stage, and the β-globin gene is transcribed and expressed specifically after birth. A powerful
enhancer called the LCR (locus control region) exists on the 5′ side of the promoter. The LCR
contains five DNase I hypersensitive sites, referred to as HS5 to HS1 starting from the 5′
side. Furthermore, HS5 contains CCCTC-binding factor (CTCF)-dependent insulator.
The structure of the lentiviral SIN vector used in gene therapy for β-thalassemia is shown in
Fig. 6. To improve safety, two stop codons were inserted into the packaging signal (ψ) of
GAG, the HS5 portion with insulator activity was deleted, and two copies of the 250 base
pair (bp) core of the cHS4 chromatin insulators (chicken β-globin insulators) were inserted
in the U3 region of the HIV 3′ LTR. Furthermore, the amino acid at the 87th position of β-
globin was changed from threonine to glutamine. This altered β-globin can be distinguished
from normal adult β-globin by high performance liquid chromatography (HPLC) analysis in
individuals receiving red blood cell transfusion and β+-thalassemia patients [33].
Figure 6. Diagram of the human β-globin gene in a lentiviral vector. HIV LTR, human immunodeficiency type-1
virus long terminal repeat; Ψ+, packaging signal; cPPT/flap, central polypurine tract/DNA flap; RRE, rev-responsive ele‐
ment; βp, human β-globin promoter; ppt, polypurine tract; HS, DNase I Hypersensitive Sites (Reproduced with color
modification from [33])
A clinical study using this vector was performed in two β-thalassemia patients. As with au‐
tologous bone marrow transplantation, some of the patients’ marrow cells were cryopre‐
served as a backup. The lentiviral vector particles containing a functional β-globin were
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introduced into the remaining cells. After the transfected cells were cultured for one week ex
vivo, some were also cryopreserved. The patients were conditioned with intravenous busul‐
fan (3.2 mg/kg/day for four days) without the addition of cyclophosphamide, before trans‐
plantation using the autologous gene-modified cryopreserved cells (Fig. 7) [34].
The first patient failed to engraft because the HSCs had been compromised by how they
were handled, not because of any issues with the gene therapy vector, and ultimately used
backup bone marrow. The second patient, as described previously, achieved long-term β-
globin production; one-third of the patient’s hemoglobin was produced by the genetically
modified cells [33].
Furthermore, the detailed examination of the transgenic cells showed significantly increased
expression of high mobility group AT-hook 2 (HMGA2), which interacts with transcription
factors to regulate gene expression, in the clones where gene insertion occurred in the
HMGA2 gene. The proportion of the HMGA2 overexpressing clones increased with time, to
over 50% of transgenic cells at 20 months after gene therapy. In this patient, the HMGA2
overexpressing cells were only 5% of all circulating hematopoietic cells and there was no
evidence of malignant transformation. However, researchers point out that there was ex‐
pressive production of a truncated form of the HMGA2 protein. Since truncated or overex‐
pressed HMGA2 is observed with some blood cancers and non-malignant expansions of
blood cells, caution is recommended with this therapy [34].
Figure 7. Gene-therapy procedure for patient with b-thalassemia. a. Hematopoietic stem cells (HSCs) are collected
from the bone marrow of a patient with β-thalassemia and maintained them in culture. b, Lentiviral-vector particles con‐
taining a functional β-globin gene were then introduced into the cells and allowed them to expand further in culture. c. To
eradicate the patient’s remaining HSCs and make room for the geneticaaly modified cells, the patient underwent chemo‐
therapy. d. The genetically modified HSCs were then transplanted into the patient (Reproduced from [34]).
Recently, researchers generated a LCR-free SIN lentiviral vector that combines two heredita‐
ry persistence of fetal hemoglobin (HPFH)-activating elements, resulting in therapeutic lev‐
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els of Aγ-globin protein produced by erythroid progenitors derived from thalassemic HSCs
[35]. Both lentiviral-mediated γ-globin gene addition and genetic reactivation of endoge‐
nous γ-globin genes are considered potentially capable of providing therapeutic levels of
hemoglobin F to patients with β-globin deficiency [36]. In addition, a trial of γ-globin induc‐
tion with β-globin production using mithramycin, an inducer of γ-globin expression, to re‐
move excess α-globin proteins in β-thalassemic erythroid progenitor cells was reported [37].
4.2. Fanconi anemia
Fanconi anemia is a hereditary disease characterized by cellular hypersensitivity to DNA
crosslinking agents. It leads to bone marrow failure, such as aplastic anemia, by approxi‐
mately eight years of age. Since there is a high risk of developing malignancy, HSCT has
been performed as a curative treatment for bone marrow insufficiency. Although the ten-
year probability of survival after transplant from an Human leukocyte antigen (HLA) -iden‐
tical donor is over 80%, results with other donors are not satisfactory. HSC gene therapy is
considered an alternative in cases where there is no HLA-identical donor available [38-40].
There are currently 13 discovered Fanconi anemia complement groups and 13 distinct genes
(FANCA, FANCB, FANCC, FANCD1, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCJ,
FANCL, FANCM, FANCN) have been cloned. Mutations in FANCB are associated with an X-
linked form of Fanconi anemia; mutations in the other genes are associated with autosomal
recessive transmission. Although frequencies vary by geographical region, FANCA gene ab‐
normalities are found in more than half of all Fanconi anemia patients [41]. Although one of
the major hurdles in the development of gene therapy for Fanconi anemia is the increased
sensitivity of Fanconi anemia stem cells to free radical-induced DNA damage during ex vivo
culture and manipulation, retroviral and lentiviral vectors have been successfully employed
to deliver complementing Fanconi anemia cDNA to HSCs with targeted disruptions of the
FANCA and FANCC genes [20, 42-44]. In a phase I trial of FANCA gene therapy, gene trans‐
fer was performed with patient bone marrow-derived CD34+ cells and the MSCV retroviral
vector [38]. Whether sufficient HSCs can be obtained is a potential problem in Fanconi ane‐
mia patients due to possible bone marrow insufficiency, but in this study, sufficient target
CD34+ cells were obtained from most patients. Two patients had FANCA-transduced cells
successfully infused. The procedure was safe, well tolerated, and resulted in transient im‐
provements in hemoglobin and platelet counts [39]. However, transduced cell products
were not obtained in one patient who required cryopreserved bone marrow. The first clini‐
cal study of FANCC gene therapy using a retroviral vector involved four patients. Although
functional FANCC gene expression was observed in peripheral blood and bone marrow
cells, the results were transient [43].
Engraftment efficiency of FANCA-modified cells using a lentiviral vector was studied in a
mouse model. Rapid transduction with four hours of culture using only SCF and megakar‐
yocyte growth and development factor and minimal differentiation of gene-induced cells is
better than standard 96-hour culture using a variety of cytokines, including SCF, interleu‐
kin-11, Flt-3 ligand, and IL-3 [44]. Moreover, a recent trial demonstrated enhanced viability
and engraftment of gene-corrected cells in patients with FANCA abnormalities with short
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transduction (overnight), low oxidative stress (5% oxygen), and the anti-oxidant N-acetyl-L-
cysteine [20]. Lentiviral transduction of unselected Fanconi anemia bone marrow cells medi‐
ates efficient phenotypic correction of hematopoietic progenitor cells and CD34-
mesenchymal stromal cells, with increased efficacy in hematopoietic engraftment [45]. In
Fancg -/- mice, the wild-type mesenchymal stem and progenitor cells play important roles in
the reconstitution of exogenous HSCs in vitro [46]. Recently, a new approach that directly
injects lentiviral vector particles into the femur for FANCC gene transfer in mice was able to
successfully introduce the FANCC gene to HSCs. This result provides evidence that target‐
ing the HSCs directly in their native environment enables efficient and long-term correction
of bone marrow defects in Fanconi anemia [47].
In recent years, the design of lentiviral vectors used for gene therapy in Fanconi anemia has
improved. Although the vav and phosphoglycerate kinase (PGK) promoters are relatively
weak, physiological levels of FANCA gene expression can be obtained in lymphoblastoid
cells. CMV and spleen focus-forming virus (SFFV) promoters result in overexpression of
FANCA. The PGK-FANCA lentiviral vectors with either a wild-type woodchuck hepatitis vi‐
rus posttranscriptional regulatory element (WPRE) or a mutated WPRE in the 3′ region have
higher levels of FANCA gene expression. In conclusion, lentiviral vectors with a mutated
WPRE and a PGK promoter are considered the most suitable with respect to safety and effi‐
ciency for Fanconi anemia gene therapy [48].
There was a recent interesting report on the use of induced pluripotent stem cells (iPS cell).
Instead of introducing a repaired gene into the HSCs of a patient with a FANCA gene abnor‐
mality, the modified gene was introduced into more stable somatic cells, e.g. fibroblasts, and
iPS cells were derived from the genetically modified somatic cells. If HSCs can be produced
from genetically modified iPS cells, hematological function can be efficiently reconstructed
in patients with hematologic disorders [49].
4.3. Hemophilia
Hemophilia is a common congenital coagulopathy caused by coagulation factor VIII (hemo‐
philia A) or IX (hemophilia B) deficiency. Although the genes encoding both factor VIII
(Xq28) and factor IX (Xq27) are located on the X chromosome and most cases are X-linked,
many sporadic variations have been reported. Factor substitution therapies have been used
to treat hemophilia for many years. However, there is great hope for gene therapy with he‐
mophilia because coagulation factors have short half-lives (factor VIII, 8 to 12 hours; factor
IX, 18 to 24 hours), and an inhibitor is produced in many cases. Furthermore, it is possible
for gene therapy to suppress immunogenicity by introducing a mutant protein that lacks the
domain with which the inhibitor interacts. Since both coagulation factors are usually pro‐
duced in the liver, there are few studies involving HSCs. In addition to hepatocytes, trials
introducing the modified gene directly into splenic cells, endothelial cells, myoblasts, fibro‐
blasts, etc. have been reported [50-52]. Since the factor IX gene (34 kb) is smaller than the
factor VIII gene (186 kb), hemophilia B gene therapy can be possible with an adenovirus vec‐
tor or an AAV vector. Therefore, hemophilia B is progressing more as a field of gene therapy
research even through there are five times more patients with hemophilia A [51-53].
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Recently, human factor VIII variant genes were successfully introduced into the HSCs of a
mouse with hemophilia A resulting in therapeutic levels of factor VIII variant protein ex‐
pression. This variant factor VIII has changes in the B and A2 domain in addition to the A1
domain for improved secretion and reduced immunogenicity (wild-type factor VIII has six
domains, A1, A2, B, A3, C1, and C2) [54]. To ameliorate the symptoms of hemophilia A, par‐
tial replacement of the mutated liver cells by healthy cells in hemophilia A mice was chal‐
lenged with allogeneic bone marrow progenitor cell transplantation. In this study, the bone
marrow progenitor cell-derived hepatocytes and sinusoidal endothelial cells synthesized
factor VIII, showing that autologous gene-modified bone marrow progenitor cells have the
potential to treat hemophilia [55].
4.4. Primary immunodeficiencies
Although HSCT has been widely performed as curative treatment for primary immunodefi‐
ciencies, gene therapy has been considered when there is no HLA-identical donor available.
As previously shown, the first successful gene therapy was performed in a patient with
ADA deficiency in the U.S. in 1990. Since the gene was introduced into T lymphocytes, fre‐
quent treatment was required. However, this treatment was associated with an unacceptable
level of toxicity. Since transfected vector and normal ADA gene expression in T lympho‐
cytes continued for two years after the cessation of treatment [1], gene therapy attracted at‐
tention. With advances in HSC gene-transfer technology, gene therapy for many primary
immunodeficiencies can now be considered [56].
4.4.1. SCID-X1
SCID-X1 is an X-linked disease caused by deficiency of the common γ (γc) chain in the IL-2
receptor. Because the γc chain is common to the IL-4, IL-7, IL-9, IL-15, and IL-21 receptors, in
SCID-X1 patients, there are defects in T and natural killer (NK) cells, and B cell dysfunction
are usually observed [57]. Patients begin suffering from various infections starting several
weeks after birth. Without curative treatment, such as HSCT, patients die in infancy.
In SCID-X1, since T cells are lacking, engraftment of the gene-transduced cells can be ach‐
ieved without pre-conditioning therapy. In the clinical studies of SCID-X1 patients in France
and the U.K., the MFG retroviral vector was used with HSCs obtained from the patient. Af‐
ter gene therapy, many patients had improvements in immune function. However, since the
genes regulating lymphocyte proliferation, such as LIM domain only 2 (LMO2), Bmi1, cyclin
D2 (CCND2) are near the gene insertion region, there was a high frequency of T-cell leuke‐
mia after treatment. Furthermore, in the patients who developed leukemia, additional chro‐
mosomal changes, including activating mutations of Notch1, changes in the T cell receptor β
region, and deletion of tumor suppressor genes, e.g. cyclin-dependent kinase-2A (CDKN2A)
were observed [58]. Almost gene integration sites by the retroviral vector were inside or
near genes that are highly expressed in CD34 positive stem cells. Furthermore, the activity
of protein kinases or transferases coded by these activated genes was stronger in CD3 posi‐
tive T cells than CD34 positive cells [59]. Thus, gene integration mediated by a retrovirus in‐
fluences the target cell’s dormant capacity for survival, engraftment, and proliferation.
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Although continuous T cell production was founded in many cases, there was little recon‐
struction of myeloid cells and B cells, and some patients required continuous immunoglobu‐
lin substitution therapy. The use of conditioning therapy is also related to immunological
reconstruction after γc chain gene therapy. There is decreased NK cell reconstruction with‐
out conditioning therapy, so conditioning chemotherapy is required for the engraftment of
undifferentiated stem cells [58]. A trial of SCID-X1 gene therapy in the U.S. involved three
patients ranging from 10 to 14 years of age. They had poor immunological recovery after al‐
lergenic HSCT and T cell recovery was only observed in the youngest patient, suggesting
there is a limit to the recovery of the function of the thymus in older children [60].
To study whether activation of genes near the region of gene insertion or inserted γc chain
gene expression itself induces oncogenicity during SCID-X1 gene therapy, a study of the hu‐
man γc chain gene being expressed under the control of the human CD2 promoter and LTR
(CD2- γc chain gene) was performed in mice. When the CD2- γc chain gene was expressed
in transgenic mice, a few abnormalities involving T cells were observed, but tumorigenesis
was not observed and T and B cell functions were recovered in γc chain-gene deficient mice.
This study demonstrated that when the γc ฀c chain gene is expressed externally, SCID-X1
may be treated safely [61].
Although SIN vectors were developed from earlier retroviral [62] or lentiviral vectors [63] to
reduce the risk of oncogenicity in SCID-X1 gene therapy, genotoxicity unrelated to muta‐
tions in gene insertion regions or γc chain gene overexpression have been reported with len‐
tiviral vectors in recent years, and it seems that more sophisticated vector development is
required [64].
4.4.2. ADA-SCID
ADA is an enzyme that catalyzes the conversion of purine metabolism products adenosine
and deoxyadenosine into inosine or deoxyinosine. ADA-SCID is an autosomal recessive dis‐
ease that results in the accumulation of adenosine, deoxyadenosine, and deoxyadenosinetri‐
phosphate (dATP). Accumulated phosphorylated purine metabolism products act on the
thymus and cause the maturational or functional disorder of lymphocytes. Because ADA-
SCID patients have both T and B cell production fail, patients have a severe combined im‐
munodeficiency disease with a clinical presentation similar to SCID-X1 results, but unlike
SCID-X1, many patients have a low level of T cells. Although enzyme replacement therapy
with polyethylene glycol–modified bovine ADA (PEG-ADA) was developed to treat ADA-
SCID, it is limited by the development of neutralizing antibodies and the cost of lifelong
treatment.
In ADA-SCID, since T cell counts are increased by PEG-ADA, gene therapy to increase pe‐
ripheral T cell counts was attempted during the early stages of gene therapy. Although ad‐
verse events were not observed and continuous expression of ADA was achieved in many
patients, reconstruction of immune function was not obtained and substitution therapy with
PEG-ADA remained necessary. Therefore, HSCs were no longer the target of gene therapy
for ADA-SCID. Since ADA-SCID patients have T cells, nonmyeloablative conditioning was
performed to achieve gene-transduced HSC engraftment [25, 65].
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In a joint Italian-Israeli study started in 2000, ten ADA-SCID children were infused with
CD34 positive cells transduced with a MoMLV retroviral vector containing the ADA gene
after  nonmyeloablative  conditioning  with  busulfan  (2mg/kg/day  for  two  days).  T  cell
counts or function were improved in nine out of the ten patients, and PEG-ADA was dis‐
continued in eight.  Many patients also had improvements in B or NK cell  function, and
immunoglobulin  substitution therapy was discontinued in  five  patients.  Although some
patients  had serious adverse events  including prolonged neutropenia,  hypertension,  Ep‐
stein-Barr virus infection, and autoimmune hepatitis, there were no cases of treatment-in‐
duced leukemia [25].
As with SCID-X1, the retroviral vector gene insertion region is also near genes that control
cell proliferation or self-duplication, such as LMO2, or proto-oncogenes [66]. In clinical stud‐
ies performed in France, the U.S., and the U.K., none of the ADA-SCID patients had adverse
events related to insertional mutagenesis, such as leukemia [67, 68]. Thus, HSC gene therapy
for ADA-SCID using a lentiviral vector [69] is expected to become the alternative therapy in
cases without a suitable donor for HSCT [70]. As an alternative to HSC-based gene therapy,
a study using an AAV vector has reported ADA gene expression in various tissues, includ‐
ing heart, skeletal muscle, and kidney [71].
4.4.3. CGD
CGD is a disease caused by an abnormality in nicotinamide dinucleotide phosphate
(NADPH) oxidase expressed in phagocytes, resulting in failure to produce reactive oxygen
species and decreased ability to kill bacteria or fungi after phagocytosis. NADPH oxidase
consists of gp91phox (Nox2) and p22 phox which together constitute the membrane-spanning
component flavocytochrome b558 (CYBB), and the cytosolic components p47phox, p67phox,
p40phox, and Rac. CGD is caused by a functional abnormality in any of these components.
Mutations in gp91phox on the X chromosome account for approximately 70% of CGD cases.
CGD patients are afflicted with recurrent opportunistic bacterial and fungal infections, lead‐
ing to the formation of chronic granulomas. Although lifelong antibiotic prophylaxis re‐
duces the incidence of infections, the overall annual mortality rate remains high (2%–5%)
and the success rate of HSCT is limited by graft-versus-host-disease and inflammatory flare-
ups at infected sites [56].
In the initial trials of CGD gene therapy without any conditioning therapy, p47phox or gp91phox
gene was inserted using a retroviral vector. The inserted gene was expressed in peripheral
blood granulocytes three to six weeks after re-infusion and mobilization by granulocyte col‐
ony-stimulating factor (G-CSF), but there was no clinical effect within six months [72-74].
In a German study where gp91phox was inserted with busulfan conditioning (8mg/kg), there
were fewer infections after gene therapy. Gene expression was observed in 20% of leuko‐
cytes in the first month, rising to 80% at one year. However, in the gene insertion region
there are genes related to myeloid cell proliferation, such as myelodysplastic syndrome 1-eco‐
tropic virus integration site 1 (MDS1/EVI1), PR domain containing protein 16 (PRDM16), SET
binding protein 1 (SETBP1). Two patients developed myelodysplasia [75]. These two patients
had monosomy 7, considered to be related to EVI1 activation. One died of severe sepsis 27
Recent Advances in Hematopoietic Stem Cell Gene Therapy
http://dx.doi.org/10.5772/53587
121
months after gene therapy. Although the gene-inserted cells remained expressed in this pa‐
tient, methylation of the CpG site in the LTR of the viral vector was observed and the ex‐
pression of the inserted gp91phox gene was decreased. Interestingly, methylation was
restricted to the promoter region of the LTR; the enhancer region was not methylated.
Therefore, although gp91phox gene expression was decreased, the activation of EVI1 near the
inserted region occurred, leading to clonal proliferation [76]. Since there is a possibility that
the transcription activity of genes related to myeloid cell proliferation near the gene inser‐
tion site will be increased, there remains a concern about tumorigenesis with peripheral
stem cells mobilization by G-CSF in CGD patients, as with X-SCID [74].
Recently, next-generation gene therapy for CGD using lineage- and stage-restricted lenti‐
viral  vectors  to  avoid  tumorigenesis  [77]  and  novel  approaches  involving  iPSs  derived
from CGD patients using zinc finger nuclease (ZFN)-mediated gene targeting were stud‐
ied [78]. Specific gene targeting can be performed in human iPSs using ZFNs to induce se‐
quence-specific  double-strand  DNA  breaks  that  enhance  site-specific  homologous
recombination. A single-copy of gp91phox  was targeted into one allele of the "safe harbor"
AAVS1 locus in iPSs [79].
4.4.4. Wiskott-Aldrich Syndrome (WAS)
WAS is  a  severe X-linked immunodeficiency caused by mutations in the gene encoding
the WAS protein (WASP), a key regulator of signaling and cytoskeletal reorganization in
hematopoietic cells. Mutations in WAS gene result in a wide spectrum of clinical manifes‐
tations ranging from relatively mild X-linked thrombocytopenia to the classic WAS pheno‐
type characterized by thrombocytopenia, immunodeficiency, eczema, high susceptibility to
developing tumors, and autoimmune manifestations [80]. Preclinical and clinical evidence
suggest  that  WASP-expressing  cells  have  a  proliferative  or  survival  advantage  over
WASP-deficient cells, supporting the development of gene therapy [56]. Furthermore, up
to 11% of WAS patients have somatic mosaicism due to spontaneous in vivo reversion to
the normal genotype, and in WAS patients, accumulation of normal T-cell precursors are
sometimes seen [81].
In one preclinical study introducing the WAS gene into human T and B cells or mouse HSCs
using a retroviral vector, recovery of T cell function and immune reactions to infection were
observed [82, 83]. The first clinical study of WAS using HSCs involved two young boys in
Germany. The WASP-expressing retroviral vector was transfected into CD34 positive cells
obtained by apheresis of peripheral blood. Busulfan was used for conditioning therapy
(4mg/kg/day for two days). Over two years, WASP gene expression by HSCs, lymphoid and
myeloid cells, and platelets was sustained, and the number and function of monocytes, T, B,
and NK cells normalized. Clinically, hemorrhagic diathesis, eczema, autoimmunity, and the
predisposition to severe infections were diminished. Since comprehensive insertion-site
analysis showed vector integration near multiple genes controlling growth and immunolog‐
ic responses in a persistently polyclonal hematopoiesis, careful monitoring for tumorigene‐
sis is necessary, as with SCID-X1 and CGD [84, 85].
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SIN lentiviral vectors using the minimal domain of the WAS promoter or other ubiquitous
promoters, such as the PGK promoter, are currently being developed for WAS gene therapy.
Preclinical studies using the HSCs obtained from mice or human patients have yield good
results in terms of gene expression and genotoxicity [86-90].
Since a study using human embryonic stem cells (hESCs) and WAS-promoter–driven lenti‐
viral vectors labeled by green fluorescent protein (GFP) showed highly specific gene expres‐
sion in hESCs-derived HSCs, the WAS promoter will be used specifically in the generation
of hESC-derived HSCs [91].
4.4.5. Janus Kinase 3 (JAK3) deficiency
JAK3 deficiency is characterized by the absence of T and NK cells and impaired function of
B cells, similar to SCID-X1. Treatment consists of HSCT with an HLA-identical or HLA-hap‐
lo-identical donor, often the parents of the patient, with T cell depletion. Engraftment is suc‐
cessful in most cases.
Although the recovery of T cell function is usually observed after HSCT, there are usually
no improvements in B or NK cell function [92]. One case report involved introduction of
JAK3 into the patient’s bone marrow CD34 positive cells using the MSCV retroviral vector.
In this study, immunological recovery was not achieved although gene expression was ob‐
served for seven months [93]. Since JAK activation can cause T-cell lymphoma, tumorigene‐
sis remains a concern with JAK gene therapy [92].
4.4.6. Purine Nucleoside Phosphorylase (PNP) deficiency
PNP metabolizes adenosine into adenine, inosine into hypoxanthine, and guanosine into
guanine. PNP deficiency is an autosomal recessive metabolic disorder characterized by le‐
thal T cell defects resulting from the accumulation of products from purine metabolism.
In PNP-deficient mice, transplantation of bone marrow cells transduced with a lentiviral
vector containing human PNP resulted in human PNP expression, improved thymocyte ma‐
turation, increased weight gain, and extended survival. However, 12 weeks after transplant,
the benefit of PNP-transduced cells and the percentage of engrafted cells decreased [94].
4.4.7. Leukocyte Adhesion Deficiency type 1 (LAD-1)
LAD-1 is a primary immunodeficiency disease caused by abnormalities in the leukocyte in‐
tegrin CD11/CD18 heterodimer due to mutations in the CD18 gene. It is similar to canine
leukocyte adhesion deficiency (CLAD). LAD-1 patients begin experiencing repeated serious
bacterial infections immediately after birth.
In order to suppress gene activation near the gene insertion region in CLAD and to obtain
the sufficient expression of the CD18 gene, researches have used various promoters with a
lentiviral vector or foamy virus, a retroviral vector. In vivo animal experiments using a PGK
or an elongation factor 1α promoter did not lead to symptom improvement [95-97], but im‐
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provement was seen with CD11b and CD18 promoters, respectively, with a SIN lentiviral
vector in one animal study [98].
4.5. Mucopolysaccharidosis (MPS)
MPS is a general term for diseases characterized by glycosaminoglycan (GAG) accumula‐
tion into lysosomes as a result  of  deficiencies in lysosomal enzymes that degrade GAG.
Although there are more than ten enzymes that are known to degrade GAG, MPS is div‐
ided  into  seven  types:  type  I  (α-L-iduronidase  deficiency,  Hurler  syndrome,  Sheie  syn‐
drome,  Hurler-Sheie  syndrome),  type  II  (iduronate  sulfatase  deficiency,  Hunter
syndrome),  type III  (heparan N-sulfatase deficiency,  α-N-acetylglucosaminidase deficien‐
cy,  α-glucosaminidase  acetyltransferase  deficiency,  N-acetylglucosamine  6-sulfatase  defi‐
ciency,  Sanfilippo  syndrome),  type  IV  (galactose  6-sulfatase  deficiency,  Morquio
syndrome),  type  VI  (N-acetylgalactosamine  4-sulfatase  deficiency,  Maroteaux-Lamy syn‐
drome), type VII (β-glucuronidase deficiency, Sly syndrome), and type IX (hyaluronidase
deficiency).  Type II  is  X-linked;  the other types are autosomal recessive.  Although lyso‐
somes are found in almost all cells, MPS mainly affects internal organs such as the brain,
heart, bones, joints, eyes, liver, and spleen. The extent of disease, including mental retar‐
dation, varies with MPS type.
In types I, II, and VI, enzyme replacement therapy is performed. HSCT is performed in
types I, II, IV, and VII. Gene therapy for types I, II, III, and VII type have been investigated.
There are trials using an AAV or adenovirus vector to insert the modified gene into various
cell types, including hepatocytes, muscle cells, myoblasts, and fibroblasts [99].
The first study of HSC gene therapy for MPS using a retroviral vector was performed on
type VII mice in 1992, resulting in decreased accumulation of GAG in the liver and spleen
but not in the brain and eyes [100]. Subsequent studies in type I and III animal models
showed decreases in GAG accumulation in the kidneys and brain. Introductory efficiency
and immunological reactions are considered challenges in HSC gene therapy for MPS [99].
Restoring or preserving central nervous system (CNS) function is one of the major chal‐
lenges  in  the  treatment  of  MPS.  Since  replaced  enzymes  easily  cannot  pass  the  blood-
brain  barrier  (BBB),  a  high  dose  of  enzyme  is  needed  to  improve  CNS  function.  Gene
therapy  faces  the  same  challenge.  Even  with  high  expression  of  enzyme  by,  for  exam‐
ple,  hepatocytes,  the  BBB  prevents  efficient  delivery  into  the  CNS.  When  a  lentiviral
vector is  directly injected into the body,  gene expression in brain tissue is  observed,  al‐
though  the  underlying  mechanism  is  unknown.  There  are  also  trials  where  AAV  vec‐
tors  are  directly  injected  into  the  CNS  of  mice  or  dogs  and  gene  expression  was
observed in brain tissue [99].
Recently, a lentiviral vector using an ankyrin-1-based erythroid-specific hybrid promoter/
enhancer (IHK) was used with HSCs to obtain gene expression only in erythroblasts for type
I MPS. This approach resulted in decreased accumulation of GAG in the liver, spleen, heart,
and CNS via enzyme expression in erythroblasts [101].
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4.6. Gaucher disease
Gaucher disease is the most common lysosomal storage disorder. It is caused by deficiency of
glucocerebroside-cleaving enzyme (β-glucocerebrosidase), resulting in the accumulation of
glucocerebroside in the reticuloendothelial system [102]. This autosomal recessive disease
presents with hepatosplenomegaly, anemia, thrombocytopenia, and convulsions with or with‐
out mental retardation. It is classified into three types based on the clinical course or existence
of neurological symptoms: type I (non-neuropathic, adult type), type II (acute neuropathic, in‐
fantile type), and type III (chronic neuropathic, juvenile type). Enzyme replacement therapy
has been established in type I. As with MPS, since it is difficult to improve CNS symptoms with
enzyme replacement therapy, HSCT is used, especially with type III. Gene therapy is consid‐
ered in cases with little improvement with enzyme replacement therapy [103].
For Gaucher disease without CNS symptoms, a animal model using an AAV vector to pro‐
duce enzyme in hepatocytes yielded good results [103]. HSC gene therapy using a retroviral
vector was attempted in type I mice. The treated cells had higher β-glucocerebrosidase activ‐
ity than the HSCs from wild-type mice. Glucocerebroside levels normalized five to six
months after treatment and no infiltration of Gaucher cells could be observed in the bone
marrow, spleen, and liver [104]. In recent years, development of lentiviral vectors including
the human glucocerebrosidase gene [105] and low-risk HSCT with nonmyeloablative doses
of busulfan (25mg/kg) and no radiation therapy have been attempted in mice [106].
4.7. X-ALD
X-ALD is a peroxisomal disease in which a lipid metabolism abnormality causes demyelina‐
tion of CNS tissues and dysfunction of the adrenal gland. It results from mutations in the
ATP-binding cassette sub-family D (ABCD1) gene that codes for the adrenoleukodystrophy
(ALD) protein. Behavioral disorders, mental retardation, or both occur by the age of five or
six. Once symptoms appear, they progress to gait disorder and visual impairment within
several months and the prognosis is poor. Increased levels of very long chain fatty acids
(VLCFA), such as C25:0 or C26:0, are observed in the CNS, plasma, erythrocytes, leucocytes,
etc. If the neurological defects are not severe, arrest of or improvement in symptoms can be
obtained with HSCT [107].
One study has reported the introduction of wild-type ABCD1 using a lentiviral vector into pe‐
ripheral blood CD34 positive cells of two patients with no HLA-identical donor. The patients
received a transfusion of autologous gene-modified cells after myeloablative conditioning
therapy. At three years of follow-up, ALD proteins were expressed in approximately 7–14% of
neutrophils, monocytes, and T cells. Clinically, cerebral demyelination stopped 14 and 16
months after gene therapy, respectively, similar to results with allergenic HSCT [108, 109].
5. Conclusion
Gene therapy using HSCs was outlined. HSCT with HSCs can replace all of the patient’s
original HSCs with donor HSCs. Therefore, gene therapy using HSCs is an alternative if the
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patient does not have an HLA-identical donor or cannot tolerate the conditioning regimen
or other HSCT-related side effects. Fully myeloablative or nonmyeloablative conditioning
regimens are still necessary to eliminate potential competition within the bone marrow com‐
partment, in an attempt to increase the number of gene-modified HSCs or progenitors that
produce the therapeutic enzyme or protein. With gene therapy, eliminating the risk of im‐
mune reactions against the transgene is necessary. Lentiviral vectors in clinical use must not
be contaminated by replication-competent recombinant vectors related to the parent HIV-1
virus. The main risk of retrovirus- or lentivirus-mediated gene therapy may prove to be in‐
sertional mutagenesis caused by random retroviral integration leading to activation of pro‐
to-oncogenes or inactivation of tumor-suppressor genes, ultimately leading to malignancy
[107]. However, with advances in gene introduction technology, such as the development of
the SIN vector and advances in cell or gene-region targeting, gene therapy can be done more
safely and efficiently. Furthermore, since cells more immature than HSCs, i.e., iPS cells, are
available, further advances in HSC gene therapy are expected in the future.
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